Friday, October 6, 2023

Amgen Completes $27.8B Acquisition Of Horizon Therapeutics

Thousand Oaks-based Amgen has completed its acquisition of Horizons Therapeutics plc. in a deal worth $27.8 billion. According to Amgen, it paid $116.50 per share in cash for horizon Therapeutics. Horizon owns a number of treatments for rare inflammatory diseases. Amgen has been working through the acquisition of Horizon since 2022, and only recently cleared a number of regulatory hurdles to complete the deal.